3Athyros VG, Katsiki, Karagiannis A, et al. ACC, AHA. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults [J]. Curr Med Res Opin, 2014, 4(1): 1-5. 被引量：1
4Kones R. Primary prevention of coronary heart disease: integration of new data,evolving views, revised goals, and role of ro suvastatin in mangement. A comprehensive survey[J]. Drug Des Devel Ther, 2011,5(1): 325-380. 被引量：1
5Sterling IL, Peoria IL. An update on the benefits and risks of rosuvastatin therapy[J]. Postgrad Med, 2014, 126(2): 7-17. 被引量：1
6Bener A, Dogam M, AL-Hamaq Ao. Comparison of efficacy, safety, and cost-effectivness of various statins in dyslipidemic diabetic patients[J]. Indian J Pharmacol, 2014, 46(1): 88-93. 被引量：1
8Roan JN, Fang SY, Chang SW, et al. Rosuvastatin improves vascular function of arteriovenous fistula in a diabetic rat model [J]. J Vase Surg, 2012, 56(5): 1381-1389. 被引量：1
9Koening W. High-sensitivity C-reactive protein and atherosclerotic disease: from improved risk prediction to risk-guided therapy[J], lnt J Cardiol, 2013, 168(6): 5126-5134. 被引量：1
10Cimato TR, Palka BA. Fractalkine (CX3CL1), GM-CSF and VEGF-a levels are reduced by statins in adult patients [J]. Clin Transl Med, 2014, 3(1): 14. 被引量：1
